Refractive correction

Refractive correction is the medical process of neutralizing a refractive error to provide clear vision, typically addressing conditions such as myopia, hyperopia, astigmatism, and presbyopia (National Eye Institute, 2023). It is not a biological molecule, receptor, or enzyme, but rather a clinical objective or procedure. Correction is primarily achieved through the use of corrective lenses (glasses and contact lenses) or refractive surgery, such as LASIK or PRK, which reshapes the cornea to alter its refractive power (StatPearls, 2023). Pharmacological interventions related to refractive correction include the use of cycloplegic agents to paralyze accommodation during eye exams or low-dose muscarinic antagonists like atropine to slow the progression of myopia in children (American Academy of Ophthalmology, 2023). Because Refractive correction describes a therapeutic goal or physiological adjustment rather than a specific molecular entity, it is classified as an incorrect target for drug discovery databases.

Other names

Vision correctionCorrection of refractive errorAmetropia correction

Refractive correction is a clinical outcome achieved through optical or surgical means; pharmacological agents used in this context typically act as muscarinic antagonists to inhibit accommodation or slow axial elongation, or as agonists to induce miosis (American Academy of Ophthalmology, 2023).